Citations

Showing 10 of 108104 citations.

Lynch Syndrome–Associated Colorectal Cancer
Sinicrope, Frank A.

Mayo Clinic

New England Journal of Medicine | August 22, 2018 | Volume: 379 | Issue: 8 | Pages: 764-773

10.1056/nejmcp1714533 | PMID 30134129 Get It

Fueling the FIRES: Hemophagocytic lymphohistiocytosis in febrile infection‐related epilepsy syndrome
Farias‐Moeller, Raquel , LaFrance‐Corey, Reghann G., Bartolini, Luca , Wells, Elizabeth, Baker, Meredith , Doslea, Alyssa, Suslovic, William, Greenberg, Jay , Carpenter, Jessica L. , Howe, Charles L. , Lafrance-Corey, Reghann , Howe, Charles L , Greenberg, Jay

Mayo Clinic

Epilepsia | August 22, 2018 | Volume: 59 | Issue: 9 | Pages: 1753-1763

10.1111/epi.14524 | PMID 30132834 Get It

SummaryObjectivesAlthough secondary hemophagocytic lymphohistiocytosis (HLH) has been reported in children with critical illness of various etiologies, it has not been reported in patients with febrile infection–related epilepsy syndrome (FIRES). We describe a series of patients with concurrent HLH and FIRES in an effort to establish common pathophysiologic abnormalities.MethodsFive patients with FIRES who were assessed for HLH were identified from a neurocritical care database. All were previously healthy and had extensive diagnostic testing. All had clinical deterioration with multiorgan dysfunction prompting HLH screening 20‐29 days after hospitalization. Markers for inflammatory dysregulation were assessed in cerebrospinal fluid (CSF) and serum at various time points. Outcomes were assessed 6 months after presentation.ResultsThree patients met clinical criteria for secondary HLH. Elevation of specific cytokines/chemokines was variable. CSF neopterin, high mobility group box 1 (HMGB1), and C‐X‐C motif chemokine ligand 8 (CXCL8) were significantly elevated in all. Interleukin‐1β (IL‐1β) and IL‐18 were not elevated in any of the samples. Treatment and outcomes were variable.SignificanceWe describe 3 patients with HLH and FIRES. The co‐occurrence of these 2 rare disorders suggests the possibility of a common immune dysregulation phenotype prolonging epileptogenesis. HLH screening in critically ill patients with FIRES may yield a broader understanding of shared inflammatory processes.
Hyponatremia in Cirrhosis: Implications for Liver Transplantation
Leise, Michael D. , Leise, Michael, Cárdenas, Andrés

Mayo Clinic

Liver Transplantation | August 22, 2018 | Volume: 24 | Issue: 11 | Pages: 1612-1621

10.1002/lt.25327 | PMID 30129266 Get It

Hyponatremia in cirrhosis is defined as a serum sodium level ≤130 mEq/L and occurs in approximately 22% of patients with cirrhosis. The appearance of hyponatremia in patients with cirrhosis portends a poor prognosis before liver transplantation (LT), independent of the Model for End‐Stage Liver Disease (MELD) score. With the development of the MELD‐sodium score, the management of hyponatremia has become more relevant than ever before. Overcorrection of hyponatremia before LT or perioperatively can lead to the devastating neurologic condition known as osmotic demyelination syndrome, which is often irreversible and fatal. Therefore, the most important tenet of hyponatremia is to avoid correcting the serum sodium by ≥8 mEq/L in a 24‐hour period. Treatment of hyponatremia is highly challenging. The vast majority of patients with cirrhosis have chronic hypervolemic hyponatremia. Fluid restriction increases serum sodium levels, but tolerance and compliance are significant barriers. Diuretic withdrawal is helpful but contributes to worsening fluid overload. There are limited data to support use of intravenous concentrated albumin solutions. The use of the arginine vasopressin antagonists (“vaptans”) is contentious; however, they may have a limited role. Risk factors for intraoperative overcorrection of serum sodium include increased utilization of packed red blood cell and fresh frozen plasma transfusions, which are often unavoidable. Intraoperative management is evolving, and more data are needed in regard to the use of sodium‐reduced continuous venovenous hemofiltration and the use of trishydroxymethylaminomethane (Tris) to avoid excess sodium rebound. A thorough discussion of the current treatment options before and during LT is given in this review.
Temporary Portomesenteric Decompression for Splenic Vein Aneurysm During Orthotopic Liver Transplant
Dougherty, Marjorie K., Musto, Kaitlyn R., Harnois, Denise M. , Nguyen, Justin H. , Chadha, Ryan

Mayo Clinic

Liver Transplantation | August 22, 2018 | Volume: 24 | Issue: 10 | Pages: 1485-1488

10.1002/lt.25295 | PMID 30129118 Get It

Low Cure Rates in Controlled Trials of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis
Tariq, Raseen , Pardi, Darrell S. , Khanna, Sahil , Bartlett, Mark G, Tariq, Raseen , Bartlett, Mark G

Mayo Clinic

Clinical Infectious Diseases | August 22, 2018 | Volume: 68 | Issue: 8 | Pages: 1351-1358

10.1093/cid/ciy721 | PMID 30957161 Get It

Reply: Two cases of CLIPPERS with increased number of perivascular CD20-positive B lymphocytes
Guo, Yong , Tobin, W. Oliver , Keegan, B. Mark

Mayo Clinic

Brain | August 22, 2018 | Volume: 141 | Issue: 10 | Pages: e76-e76

10.1093/brain/awy236 | PMID 30203037 Get It

Carotid revascularization and medical management for asymptomatic carotid stenosis – Hemodynamics (CREST-H): Study design and rationale
Marshall, Randolph S. , Lazar, Ronald M. , Liebeskind, David S. , Connolly, E. Sander , Howard, George , Lal, Brajesh K. , Brott, Thomas G. , Liebeskind, David S. , Howard, George , Huston, John , Meschia, James F. , Marshall, Randolph S.

Mayo Clinic

International Journal of Stroke | August 22, 2018 | Volume: 13 | Issue: 9 | Pages: 985-991

10.1177/1747493018790088 | PMID 30132751 Get It

Rationale For patients with asymptomatic high-grade carotid stenosis, clinical investigations have focused on preventing cerebral infarction, yet stenosis that reduces cerebral blood flow may independently impair cognition. Whether revascularization of a hemodynamically significant carotid stenosis can alter the course of cognitive decline has never been investigated in the context of a randomized clinical trial. Hypothesis Among patients randomized in the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis (CREST-2) trials, the magnitude of treatment differences (revascularization versus medical management alone) with regard to cognition will differ between those with flow impairment compared to those without flow impairment. Sample size We will enroll approximately 500 patients from CREST-2, of which we anticipate 100 will have hemodynamic impairment. We estimate 93% power to detect a clinically meaningful treatment difference of 0.5 SD. Methods and design We will use perfusion-weighted magnetic resonance imaging to stratify by hemodynamic status. Linear regression will compare treatment differences, controlling for baseline cognitive status, age, depression, prior cerebral infarcts, silent infarction, white matter hyperintensity volume, and cerebral microbleeds. Study outcomes The primary outcome is change in cognition at one year. Secondary outcomes include silent infarction, change in white matter hyperintensity volume, number of cerebral microbleeds, and cortical thickness over one year. Discussion If cognitive impairment can be shown to be reversible by revascularization, then we can redefine “symptomatic carotid stenosis” to include cognitive impairment and identify a new population of patients likely to benefit from revascularization. Trial Registration US National Institutes of Health (NIH) clinicaltrials.gov NCT03121209
Representative cDNA Libraries and Their Utility in Gene Expression Profiling
Endege, Wilson O., Steinmann, Katharina, Boardman, L.A., Thibodeau, Steven, Schlegel, Robert, Steinmann, K.E., Boardman, L.A.

Mayo Clinic

BioTechniques | August 22, 2018 | Volume: 26 | Issue: 3 | Pages: 542-550

10.2144/99263cr04 | PMID 10090998 Get It

Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing
Lanktree, Matthew B. , Haghighi, Amirreza , Guiard, Elsa, Iliuta, Ioan-Andrei, Song, Xuewen , Harris, Peter C. , Paterson, Andrew D. , Pei, York , Harris, Peter C , Paterson, Andrew

Mayo Clinic

Journal of the American Society of Nephrology | August 22, 2018 | Volume: 29 | Issue: 10 | Pages: 2593-2600

10.1681/asn.2018050493 | PMID 30135240 Get It

Background Estimating the prevalence of autosomal dominant polycystic kidney disease (ADPKD) is challenging because of age-dependent penetrance and incomplete clinical ascertainment. Early studies estimated the lifetime risk of ADPKD to be about one per 1000 in the general population, whereas recent epidemiologic studies report a point prevalence of three to five cases per 10,000 in the general population. Methods To measure the frequency of high-confidence mutations presumed to be causative in ADPKD and autosomal dominant polycystic liver disease (ADPLD) and estimate lifetime ADPKD prevalence, we used two large, population sequencing databases, gnomAD (15,496 whole-genome sequences; 123,136 exome sequences) and BRAVO (62,784 whole-genome sequences). We used stringent criteria for defining rare variants in genes involved in ADPKD ( PKD1 , PKD2 ), ADPLD ( PRKCSH , SEC63 , GANAB , ALG8 , SEC61B , LRP5 ), and potential cystic disease modifiers; evaluated variants for quality and annotation; compared variants with data from an ADPKD mutation database; and used bioinformatic tools to predict pathogenicity. Results Identification of high-confidence pathogenic mutations in whole-genome sequencing provided a lower boundary for lifetime ADPKD prevalence of 9.3 cases per 10,000 sequenced. Estimates from whole-genome and exome data were similar. Truncating mutations in ADPLD genes and genes of potential relevance as cyst modifiers were found in 20.2 cases and 103.9 cases per 10,000 sequenced, respectively. Conclusions Population whole-genome sequencing suggests a higher than expected prevalence of ADPKD-associated mutations. Loss-of-function mutations in ADPLD genes are also more common than expected, suggesting the possibility of unrecognized cases and incomplete penetrance. Substantial rare variation exists in genes with potential for phenotype modification in ADPKD.